Overview

Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea

Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn more about how to improve treatment of patients with diarrhea predominant Irritable Bowel Syndrome (IBS-D) symptoms.Included patients will be requested to answer online surveys and will undergo treatment with rifaximin. Hydrogen breath testing and biologic samples collection will also be completed during the study.
Phase:
Phase 4
Details
Lead Sponsor:
University of Michigan
Collaborator:
Commonwealth Diagnostics International, Inc.
Treatments:
Lactulose
Rifamycins
Rifaximin